China Resources Double-Crane Pharmaceutical (SHA:600062) received a drug registration certificate from the National Medical Products Administration for its oxcarbazepine tablets, according to a Shanghai bourse filing on Tuesday.
The certificate was received through subsidiary China Resources Double-Crane Xiangzhong Pharmaceutical (Hunan).
The drug is used as treatment for primary generalized tonic-clonic seizures and partial seizures, with or without secondary generalized seizures, for children and adults.